GlassScriptPhysician profile
Kelly E Pavelich
NPI 1265883227
$9,584.65
in general payments reported to CMS, 2019-2025
27 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $759 · 2022: $542 · 2023: $2,829 · 2024: $3,985 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,420 · Food and Beverage: $3,549 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,420.00 |
| Food and Beverage | $3,548.51 |
| Education | $315.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,873.18 | 2023-2024 | Cabtreo, Jublia |
| Abbvie INC. | $1,799.92 | 2021-2025 | |
| Leo Pharma INC. | $1,213.55 | 2022-2024 | Adbry |
| Incyte Corporation | $1,020.00 | 2023 | |
| Genzyme Corporation | $658.77 | 2021-2025 | |
| Amgen INC. | $408.23 | 2022-2025 | Otezla, Otezla |
| Pfizer INC. | $395.99 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $390.28 | 2021-2025 | |
| Janssen Biotech, INC. | $336.75 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $223.69 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $214.78 | 2022-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $174.98 | 2024-2025 | |
| Dermavant Sciences, INC. | $166.02 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $131.31 | 2022-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $84.33 | 2021-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $82.50 | 2024-2025 | Bimzelx |
| Organon LLC | $78.75 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $71.88 | 2021 | |
| Lilly USA, LLC | $54.10 | 2022-2023 | Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $49.61 | 2023-2024 | Zoryve |
| Verrica Pharmaceuticals INC. | $31.25 | 2023-2024 | Ycanth |
| Epi Health, LLC | $24.91 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.40 | 2023 | |
| Journey Medical Corporation | $21.71 | 2025 | |
| Dermira, INC. | $20.84 | 2021 | |
| Almirall LLC | $18.79 | 2021 | |
| Organogenesis INC. | $16.13 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Pavelich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.